Arena Pharma (ARNA) BELVIQ Trends Remain Underwhelming, BMO Capital Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
- Devon Energy to sell Eagle Ford assets to Crescent Energy for $4.2B
Arena Pharma (ARNA), Eisai Will Present Lorcaserin HCl Data at Two Upcoming Meetings
May 14, 2015 8:02 AM EDTEisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that lorcaserin HCl data will be presented at the following medical meetings:
American Thoracic Society International Conference taking place in Denver, Colorado, May 15-20, 2015Lorcaserin for Smoking Cessation Treatment in Cigarette Smokers:... MoreArena Pharma (ARNA) Tops Q1 EPS by 4c
May 11, 2015 4:09 PM EDTArena Pharma (NASDAQ: ARNA) reported Q1 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $10.56 million.
At March 31, 2015, cash and cash equivalents totaled $241.0 million, including net proceeds of $100.7 million from... More



